PT4:04 Achievement of low disease activity and remission in patients with SLE treated with dapirolizumab pegol: updated 48-week analyses from a phase 3 trial including lower glucocorticoid dose criteria

no IgG complexes on biopsy.Thus, 11 of 12 patients achieved medication-free serological remission.These findings support targeting both CD19 and BCMA in SLE/LN to achieve longterm sCR.With P1 sCR approaching 6 years, this may offer a first glimpse into the curative potential of CAR T-cell therapy in autoimmune diseases.